Welcome to our dedicated page for Neogenomics SEC filings (Ticker: NEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reimbursement swings, rapid NGS test launches, and multi-site lab expansions make NeoGenomics鈥� SEC filings dense and time-sensitive. Sifting through a 300-page 10-K to find how CMS policy shifts impact oncology diagnostics revenue isn鈥檛 trivial. That鈥檚 the problem our platform solves.
Stock Titan delivers AI-powered summaries that turn every NeoGenomics annual report 10-K simplified, each NeoGenomics quarterly earnings report 10-Q filing, and even a surprise NeoGenomics 8-K material events explained into plain-English insights. Need NeoGenomics Form 4 insider transactions real-time? We stream the data the instant executives file, flagging notable moves so you can monitor NeoGenomics insider trading Form 4 transactions without refreshing EDGAR.
Here鈥檚 what you鈥檒l uncover faster than opening a PDF:
- Segment breakouts鈥擟linical Services vs. Pharma Services鈥攑ulled directly from the latest NeoGenomics earnings report filing analysis.
- Risk-factor shifts, like payer-mix concentration, highlighted by our AI with links back to source paragraphs.
- Board and leadership pay straight from the NeoGenomics proxy statement executive compensation section.
- Alerts on NeoGenomics executive stock transactions Form 4 alongside historical pattern charts.
Whether you鈥檙e understanding NeoGenomics SEC documents with AI for a deep-dive valuation model or just checking a single NeoGenomics insider trading Form 4, our real-time engine gives you comprehensive coverage of every filing type鈥�10-K, 10-Q, 8-K, S-3, DEF 14A鈥攗pdated the moment they hit EDGAR. No more CTRL-F hunts; the insights that move oncology-focused portfolios are already distilled for you.
Neogenomics, Inc. Schedule 13G discloses that First Light Asset Management, LLC beneficially holds 9,544,749 shares of Neogenomics common stock (about 7.39% of the class). Mathew P. Arens is reported as beneficial owner of 9,784,749 shares (about 7.57%), which reflects his control of the manager plus 100,000 shares held directly and additional shares held jointly. The filing is submitted under Rule 13d-1(b), indicating these holdings are reported as passive and not intended to change or influence control of the issuer. The filing includes a joint filing agreement and identifies the reporting persons' business address.
Three related reporting persons 鈥� Greenhouse Funds LLLP, Greenhouse GP LLC and Joseph Milano 鈥� each report beneficial ownership of 7,431,147 shares of NeoGenomics common stock, representing 5.8% of the class. The filing shows no sole voting or dispositive power and reports shared voting power of 6,658,116 and shared dispositive power of 7,431,147, indicating joint control over voting and disposition rather than individual control.
The statement explains these securities are directly owned by advisory clients of Greenhouse Funds LLLP, that the holdings were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer, and includes a disclaimer limiting claimed beneficial ownership to pecuniary interest.
NeoGenomics disclosed that director Elizabeth Floegel resigned from the Company鈥檚 Board, effective immediately. The filing expressly states her resignation did not result from any disagreement with the Company on its operations, policies or practices. The notice is a straightforward governance update recorded under Item 5.02 and does not include any additional information about reasons beyond the statement or any immediate replacement for the Board seat.
This disclosure informs investors of a change in board composition while explicitly denying any dispute with management; the filing contains no financial data, operational changes or other material transactions.
Key takeaways from CEO Anthony P. Zook鈥檚 Form 4 filing (NEO, filed 6 Aug 2025):
- On 06 Aug 2025 Zook executed an open-market purchase (code P) of 17,900 common shares at $5.584, raising his direct stake to 38,066 shares; he also beneficially owns 18,900 shares via a trust.
- No shares were sold or otherwise disposed.
- Derivative holdings disclosed: 8,353 options @ $14.82 (exercisable 10 Aug 2024鈥�10 Aug 2033), 8,672 options @ $13.71 (1 Jun 2025鈥�1 Jun 2034) and a premium-priced grant of 729,927 options @ $10.44. In addition, 421,496 restricted stock units were granted on 1 Apr 2025. All awards vest ratably over three years.
The net effect is an incremental cash purchase signalling management confidence at a price well below option strikes, while the large option/RSU package further aligns incentives but introduces future dilution risk.
NeoGenomics Director Marjorie C. Green received new equity compensation grants on June 19, 2025, consisting of:
- Stock Options: Granted 16,019 options to buy common stock at an exercise price of $6.95 per share. These options will become exercisable on June 1, 2026, and expire on June 19, 2035.
- Restricted Stock Units (RSUs): Awarded 22,964 RSUs that will vest on June 1, 2026. Once vested, these RSUs convert to common stock with no expiration date.
This Form 4 filing represents standard director compensation equity grants. The combined awards suggest continued commitment to aligning director interests with shareholders through long-term equity incentives. All securities are held directly by the reporting person.
FAQ
What is the current stock price of Neogenomics (NEO)?
What is the market cap of Neogenomics (NEO)?
